AIS Insights AI Podcast
Paper Number
ICIS2026-2565
Paper Type
Short
Abstract
AlphaFold is a domain-specific AI that addresses a key bottleneck in early-stage drug discovery: predicting protein structures. Such a breakthrough might intuitively be expected to accelerate upstream innovation and alter how firms allocate innovation across the R&D pipeline. Prior studies mainly examine general-purpose AI or innovation outputs within a single R&D stage. Less is known about how firms shift innovation focus when domain-specific AI breaks through an industry’s core technology. Using the AlphaFold shock as a natural experiment, we construct patent-based measures of upstream and downstream R&D activities for structural biology firms and estimate a difference-in-differences model. Our results reveal a non-intuitive finding: both patent applications and granted patents decrease after the shock. Meanwhile, firms shift innovation focus from upstream drug discovery toward downstream stages closer to clinical trials and commercialization. These findings extend AI innovation research and inform biotech strategy and innovation policy.
Recommended Citation
Wu, Xia and Lu, Angela, "AlphaFold Shock: Innovation Reallocation in Structural-Biology Firms" (2026). ICIS 2026 Proceedings. 11.
https://aisel.aisnet.org/icis2026/innov/innov/11
AlphaFold Shock: Innovation Reallocation in Structural-Biology Firms
AlphaFold is a domain-specific AI that addresses a key bottleneck in early-stage drug discovery: predicting protein structures. Such a breakthrough might intuitively be expected to accelerate upstream innovation and alter how firms allocate innovation across the R&D pipeline. Prior studies mainly examine general-purpose AI or innovation outputs within a single R&D stage. Less is known about how firms shift innovation focus when domain-specific AI breaks through an industry’s core technology. Using the AlphaFold shock as a natural experiment, we construct patent-based measures of upstream and downstream R&D activities for structural biology firms and estimate a difference-in-differences model. Our results reveal a non-intuitive finding: both patent applications and granted patents decrease after the shock. Meanwhile, firms shift innovation focus from upstream drug discovery toward downstream stages closer to clinical trials and commercialization. These findings extend AI innovation research and inform biotech strategy and innovation policy.
When commenting on articles, please be friendly, welcoming, respectful and abide by the AIS eLibrary Discussion Thread Code of Conduct posted here.
Comments
15_Innovation_and_entrepreneurship